Disease-associated proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9353162
APP PUB NO 20130102544A1
SERIAL NO

13716290

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy subjects, antibodies which recognize this protein, and methods for diagnosing such conditions.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
NOVARTIS AGLICHTSTRASSE 35 BASEL 4056
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)101 RUE DE TOLBIAC PARIS 75013

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Alvarez, Carlos Riehen, CH 18 249
Hicks, David Strasbourg, FR 15 117
Léveillard, Thirry Maisons-Alfort, FR 1 2
Mohand-Said, Saddek Paris, FR 9 84
Poch, Olivier Strasbourg, FR 8 10
Sahel, Jose Alain Paris, FR 16 84

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 30, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00